We acknowledge that the UBC Vancouver campus is situated on the traditional, ancestral, and unceded territory of the xʷməθkʷəy̓əm (Musqueam).

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Is big pharma guiding federal drug policy? Impact of proposed regulations on prices & access to new medicines


You are invited! Dr. Aslam Anis will be giving a presentation as part of the SPPH Seminar Series on Friday, March 15, 2024.

Presentation: Is big pharma guiding federal drug policy? Impact of proposed regulations on prices & access to new medicines

Date & Time:
9:00am-10:00am PT, Friday, March 15, 2024

B104, School of Population and Public Health, 2206 East Mall, Vancouver, BC Canada V6T 1Z3
If attending on Zoom, please see below for the meeting link and details.
Join Zoom Meeting

Meeting ID: 697 0122 5082
Passcode: 675236

About the presentation

In February 2023, Dr. Matthew Herder resigned from the Patented Medicine Prices Review Board (PMPRB), citing the government’s failure to implement critical reforms to lower medicine costs. Health Minister Jean-Yves Duclos has denied any interference, stressing that the PMPRB is politically independent.

Dr. Anis will explore this impasse, the role of the PMPRB in drug pricing, and the future of pharmaceutical regulation in Canada.

About the presenter

Dr. Aslam Anis is Professor and Director Pro Tem at the UBC School of Population and Public Health. His research area spans across cost effectiveness of AIDS treatments, drug assessments – pharmacoeconomics, health care economics, health regulations, Health economics, rhematoid arthritis, biologic therapies.

Dr. Aslam Anis is one of Canada’s most distinguished health economists. In a career spanning more than 25 years, he has achieved international recognition for his seminal contributions to the fields of pharmacoeconomics, pharmaceutical industry regulation, and drug pricing. Dr. Anis’ current and past work is influential across a broad spectrum of health research domains including HIV/AIDS, rheumatoid arthritis, substance use and addiction treatment, among others. He has published over 200 peer-reviewed manuscripts and regularly presents at national and international conferences as an expert in his field.

Dr. Anis has also developed a reputation for leadership and administrative excellence. He is a key architect for the continuing success of the Canadian HIV Trials Network (CTN) and the Centre for Advancing Health Outcomes, where he has made remarkable contributions to the health sciences and further established himself as one of the pre-eminent health economists in Canada and internationally.

Recent Comments

No comments to show.


Comments are closed.